Abstract
“For many years generic companies were the poor relations of the
pharmaceutical industry, with modest growth rates and little or no
transnational business operations. As generics companies have grown, often by
acquisition, they have generally developed as international businesses.”
There has been a remarkable transformation in the pharmaceutical market, with
revenue growth in the generics business turning into a high growth segment. In
2006, global sales of generic pharmaceuticals were $ 77 billion.
The leading two generics companies have both generated sufficient revenues to
be described as major pharmaceutical companies. However there are also key
issues that impact the growth prospects of the generics companies, such as
fewer new therapeutic entities reaching the market- which ultimately reduces
the number of opportunities to launch new generic products. Another crucial
issue for the generics market is more biological agents. The introduction of
biosimilars has several legislative and regulatory constraints for generics
companies.
In response to some of these challenges, many leading generic companies have
pursued consolidation via mergers and acquisitions, increasing their market
muscle and improving their geographical reach. This has made the generics
market see a rush of takeovers.
Consolidation in the Generic Pharmaceutical Industry: An evolving landscape
closely examines the significant acquisitions in the industry and
forecasts which companies are shifting from single country marketing
strategies through mergers and take-overs.
Key Features of the Report:
- Solid overview of the generics market
- Tells the story behind the most competitive acquisitions- and why generics
companies are moving to lower cost manufacturing environments,
- Assesses the upcoming players in the generics market- Brazil, Mexico,
India, China and South Korea
- Identifies low penetration markets for short term revenue growth
- Profiles 11 generics companies
- Points out when the generics market will see slow growth, and why..
Companies mentioned in the report include:
- Abbott
- Actavi
- Allergan
- Apotex
- Aspen Pharmacare
- AstraZeneca
- Baxter
- Bristol-Myers
- Caraco.
- Chisie
- Cinfa
- Dr Reddy' s
- Egis
- Gedeon Richter
- GlaxoSmithKline
- Glenmark
- Greenstone (Pfizer)
- Hikma
- Hospira
- Krka
- Kyowa
- Mallinckrodt
- Merck
- Mylan
- Nichiiko
- Nicholas Piramal
- Novo Nordisk
- Par
- Perigo
- Pliva
- Ranbaxy
- Ratiopharm
- Richter
- Sandoz (Novartis)
- Sawai
- Sanofi-Aventis
- Stada
- Teva
- Torrent
- Towa
- Wockhardt
- Zambon
- Zentiva
- Zydus Cadila
Table of Contents
Executive Summary
Chapter 1: Introduction
- Introduction
- Generics companies as major pharmaceutical companies
- Consolidation to meet new challenges
Chapter 2: Overview of the Generics Market
- Introduction
- North America
- Europe
- Western Europe
- Central and Eastern Europe
- Japan
- Emerging markets
Chapter 3: New Challenges
- Introduction
- Authorised generics
- Overview
- Financial impact
- Outlook
- Generic divisions of major companies
- Impact of the innovation gap
- Biosimilars
- Introduction
- Entry barriers
- Legislative constraints
- Patents
- Regulatory factors
- Europe
- US
- Outlook
Chapter 4: Consolidation as a Strategy
- Introduction
- Benefits of consolidation
- Economies of scale
- Marketing muscle
- Geographic focus
- Battle for market leadership
- Highly competitive acquisitions
- Pliva
- Andrx
- Merck Generics
- Further consolidation
- North America
- Europe
- India
- Other markets
- Alternative strategies
Chapter 5: Emerging Players
- Introduction
- India
- China
- South Korea
- Brazil
- Mexico
Chapter 6: Company Profiles
- Introduction
- Teva
- Sandoz
- Watson
- Barr
- Merck KGaA
- Ratiopharm
- Actavis
- Stada
- Mylan
- Ranbaxy
- Dr Reddy' s
Chapter 7: Outlook
- Introduction
- Key developments
- New market opportunities
- Biosimilars
- Declining product opportunities
- Increased competition
- New strategies
- Consolidation
- Biosimilars
- Product differentiation
References
List of Figures
- Figure 2.1 Predicted market growth rates for generics, 2006-11
- Figure 2.2 Distribution of global generics revenues by market, 2006
- Figure 2.3 Growth in US generic drug sales, 1984-2006
- Figure 2.4 Market penetration of generics in European countries, 2006
- Figure 2.5 Growth rates of major Latin American markets, 2000-05
- Figure 3.1 US sales of paroxetine, July 2003-May 2004
- Figure 3.2 FDA approvals of new therapeutics, 2000-06
- Figure 6.1 Geographical distribution of Teva' s revenues, 2006
- Figure 6.2 Geographical distribution of Sandoz' s revenues, 2006
- Figure 6.3 Geographical distribution of Pliva' s revenues, 2006
- Figure 6.4 Geographical distribution of Merck KGaA' s revenues from
generics, 2006
- Figure 6.5 Geographical distribution of Actavis' s revenues, 2006
- Figure 6.6 Breakdown of Stada' s revenues, 2006
- Figure 6.7 Geographic distribution of Stada' s revenues, 2006
- Figure 6.8 Therapeutic distribution of Mylan' s revenues, 2006
- Figure 6.9 Geographic distribution of Ranbaxy' s revenues, 2006
- Figure 6.10 Geographic distribution of Dr Reddy' s revenues, fiscal 2007
- Figure 7.1 Number of significant new generic opportunities in the US,
2007-11
List of Tables
- Table 1.1 Sales of leading generics manufacturers, 2006
- Table 2.1 Total and generic pharmaceutical sales in Western European (EU)
countries, 2006
- Table 2.2 Total pharmaceutical sales in Central and Eastern European
countries, 2006
- Table 2.3 Major Latin American markets, 2006 sales
- Table 3.1 2006 sales revenues of NCEs approved by the FDA in 2001
- Table 3.2 Leading biotechnology products, 2006
- Table 4.1 Major acquisitions by Teva and Sandoz, 1996-2006
- Table 4.2 Leading Indian generics manufacturers, showing sales revenues
for fiscal 2006 (mostly year ending 31 March 2007) and market capitalisation
in April 2007
- Table 5.1 Acquisition deals made by Indian pharmaceutical companies,
2005-07
- Table 6.1 Actavis' s leading products, 2006
- Table 6.2 Stada' s leading products, 2006
医薬品
その他のカテゴリ
FAQ